Biotie Therapies - Notice to general meeting

Invitation to The Annual General Meeting of Biotie Therapies Corp.

BIOTIE THERAPIES CORP.   STOCK EXCHANGE RELEASE 27 April 2009 at 1.00
p.m.

INVITATION TO THE ANNUAL GENERAL MEETING OF BIOTIE THERAPIES CORP.

Notice is given to the shareholders of Biotie Therapies Corp. to the
Annual General Meeting to be held on 29 May 2009 at 10 a.m. at the
premises of restaurant Alabama, address Lemminkäisenkatu 14-18 B,
Turku, Finland. The reception of persons who have registered for the
meeting and the distribution of voting tickets will commence at 9.30
a.m.

A. MATTERS ON THE AGENDA OF THE ANNUAL GENERAL MEETING

At the Annual General Meeting, the following matters will be
considered:

1. Opening of the meeting

2. Calling the meeting to order

3. Election of persons to confirm the minutes and to supervise the
counting of votes

4. Recording the legality of the meeting

5. Recording the attendance at the meeting and adoption of the list
of votes

6. Presentation of the financial statements, the report of the Board
of Directors and the auditor's report for the year 2008
- Review by the CEO
- The company's equity is less than a half of the share capital, if
the capital loans are not counted among the items of the company's
shareholder' equity. Possible measures to remedy the financial
position of the company.

7. Adoption of the financial statements

8. Booking of the loss of the financial year
The Board of Directors proposes that loss of the financial year 2008
shall be transferred to the unrestricted equity and no dividend shall
be distributed.

9. Resolution on the discharge of the members of the Board of
Directors and the Managing Director from liability

10. Resolution on the remuneration of the members of the Board of
Directors
The Board of Directors proposes on the basis of the recommendation of
the Nomination and Remuneration Committee that the remuneration
payable to the members of the Board of Directors should be as
follows: EUR 3,000 per month for the Chairman and each member
residing abroad and EUR 1,500 per month for each member residing in
Finland. In addition, it is proposed that reasonable travelling
expenses for the meetings would be compensated.

11. Resolution on the number of members of the Board of Directors
The Board of Directors proposes on the basis of the recommendation of
the Nomination and Remuneration Committee that the number of members
of the Board of Directors would be seven (7).

12. Election of members of the Board of Directors
The Board of Directors proposes on the basis of the recommendation of
the Nomination and Remuneration Committee that Juha Jouhki, Ann
Hanham, Bernd Kastler, Pauli Marttila, Riku Rautsola, Christoph
Schröder and Pierre Serrure would be elected as members of the Board
of directors for the term expiring at the end of the following annual
general meeting.

13. Resolution on the remuneration of the auditors
The Board of Directors proposes on the basis of the recommendation of
the Audit Committee that the auditors' fees should be paid pursuant
to a reasonable invoice.

14. Election of auditors
The Board of Directors proposes on the basis of the recommendation of
the Audit Committee that PricewaterhouseCoopers Oy, a firm of
auditors approved by the Central Chamber of Commerce, and Mr Janne
Rajalahti, Authorised Public Accountant, would be elected as the
auditors of the company.

15. Authorizing the Board of Directors to decide on the issuance of
shares as well as the issuance of options and other special rights
entitling to shares

The Board of Directors proposes that the Annual General Meeting would
authorise the Board of Directors to resolve on one or more issues
which contains the right to issue new shares or dispose of the shares
in the possession of the company and to issue options or other
specific rights to the shares pursuant to chapter 10 of the Companies
Act. The authorisation would consist of up to 25,000,000 shares in
the aggregate. A maximum of 819,000 own shares in the possession of
the company could be conveyed.

The authorisation would not exclude the Board of Directors' right to
decide on a directed issue. The authorisation is proposed to be used
for material arrangements from the company's point of view, such as
financing or implementing business arrangements or investments or for
other such purposes determined by the Board of Directors in which
case a weighty financial reason for issuing shares, options or other
specific rights and possibly directing a share issue would exist.
Further, the authorisation could be used to create new share-based
incentive schemes.

The Board of Directors would be authorised to resolve on all other
terms and conditions of a share issue, options and other specific
share entitlements as referred to in chapter 10 of the Companies Act,
including the payment period, determination grounds for the
subscription price and subscription price or allocation of shares,
option rights or specific rights free of charge or that the
subscription price may be paid besides in cash also by other assets
either partially or entirely.

The authorisation would be effective until 30 June 2010. The Board of
Directors proposes that the authorisation shall not supersede earlier
authorisations.

16. Closing of the meeting

B. DOCUMENTS OF THE ANNUAL GENERAL MEETING

The proposals of the Board of Directors relating to the agenda of the
Annual General Meeting as well as this notice are available on Biotie
Therapies Corp.'s website at www.biotie.com. The annual report of
Biotie Therapies Corp., including the company's financial statements,
the report of the Board of Directors and the auditor's report, is
available on the above-mentioned website no later than 8 May 2009.
The proposals of the Board of Directors and the financial statements
are also available at the meeting. Copies of these documents and of
this notice will be sent to shareholders upon request. The minutes of
the meeting will be available on the above-mentioned website as from
12 June 2009.

C. INSTRUCTIONS FOR THE PARTICIPANTS IN THE ANNUAL GENERAL MEETING

1. The right to participate and registration

Each shareholder, who is registered on 19 May 2009 in the
shareholders' register of the company held by Euroclear Finland Ltd,
has the right to participate in the Annual General Meeting. A
shareholder, whose shares are registered on his/her personal
book-entry account, is registered in the shareholders' register of
the company.

A shareholder, who wants to participate in the Annual General
Meeting, shall register for the meeting no later than 25 May 2009 at
4.00 p.m. by giving a prior notice of participation. Such notice can
be given:

a) by e-mail virve.nurmi@biotie.com;
b) by telephone +358 2 274 8911; or
c) by regular mail to Biotie Therapies Corp. / Virve Nurmi,
Tykistökatu 6, FI-20520 Turku, Finland.

In connection with the registration, a shareholder shall notify
his/her name, personal identification number, address, telephone
number and the name of a possible assistant. The personal data given
to Biotie Therapies Corp. is used only in connection with the Annual
General Meeting and with the processing of related registrations.

Pursuant to chapter 5, section 25 of the Companies Act, a shareholder
who is present at the Annual General Meeting has the right to request
information with respect to the matters to be considered at the
meeting.

2. Proxy representative and powers of attorney

A shareholder may participate in the Annual General Meeting and
exercise his/her rights at the meeting by way of proxy
representation. A proxy representative shall produce a dated proxy
document or otherwise in a reliable manner demonstrate his/her right
to represent the shareholder at the Annual General Meeting. Possible
proxy documents should be delivered in originals to the company
before the last date for registration.

3. Holders of nominee registered shares

A holder of nominee registered shares, who wants to participate in
the Annual General Meeting, must be entered into the shareholders'
register of the company on 19 May 2009, the record date of the
meeting. A holder of nominee registered shares is advised to request
necessary instructions regarding the registration in the
shareholder's register of the company, the issuing of proxy documents
and registration for the Annual General Meeting from his/her
custodian bank.

4. Other information

On the date of this notice to the Annual General Meeting, 27 April
2009, the total number of shares and votes in Biotie Therapies Corp.
is 144,320,560.

In Turku, 27 April 2009

Biotie Therapies Corp.
Board of Directors

For further information, please contact:
Timo Veromaa, President and CEO, Biotie Therapies Corp.
tel. +358 2 274 8901, e-mail: timo.veromaa@biotie.com
www.biotie.com

DISTRIBUTION:

NASDAQ OMX Helsinki Ltd
Main Media